NewsTrending topic
Injectable Nivolumab: What the "5-Minute Cancer Jab" Headline Means
An under-the-skin form of the immunotherapy nivolumab is approved in the US and UK. It saves time. It is not a new drug or a cure for 15 cancers.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
What the headline says
Social media posts about a "five-minute cancer jab" keep coming back. The posts are about nivolumab, an immunotherapy medicine that has been used for years. Until now it was given through a vein (IV), usually over 30 to 60 minutes. There is now a version that goes under the skin as an injection.
The posts say it works on 15 cancers. Some readers took that to mean 15 children, or a shot that cures 15 cancers. Neither is right. It means 15 types of cancer, and it is the same medicine in a faster form.
What was approved
The US Food and Drug Administration approved nivolumab with hyaluronidase-nvhy (brand name Opdivo Qvantig) on December 27, 2024. Hyaluronidase is an added ingredient that helps the medicine spread through tissue under the skin.
FDA lists the cancers it covers. They include kidney cancer, melanoma, non-small cell lung cancer, head and neck cancer, bladder and urinary tract cancer, colorectal cancer, liver cancer, and esophageal, stomach and gastroesophageal junction cancers. Use depends on the setting. It can be given alone, as maintenance after treatment with ipilimumab, or alongside chemotherapy or cabozantinib.
It is not approved to be given together with IV ipilimumab.
In the United Kingdom, NHS England announced in April 2025 that the regulator there had approved it. NHS England said the shot takes 3 to 5 minutes, that about 1,200 patients a month in England could benefit, and that about 1,000 hours of treatment time could be saved each month. It also said about 2 in 5 current IV nivolumab patients would qualify. NHS England describes those numbers as estimates.
What the evidence shows
FDA's notice describes a trial called CheckMate-67T. It enrolled 495 people with advanced clear cell kidney cancer. Half had the injection and half had the IV form.
The trial's main goal was to show that the injection delivers a similar amount of medicine in the blood. It did. FDA also lists response rates: 24% of people on the injection and 18% on the IV form. The ranges around those two numbers overlap. So the trial does not show that the injection works better.
FDA says the safety picture was similar to the IV form. The most common side effects were tiredness, muscle and joint pain, itching, rash and cough.
What it does not mean
- It is not a new cancer drug. It is a new way to give an existing one.
- It is not a cure, and it is not a vaccine.
- It does not work on every cancer, or on every person with those cancers. Your cancer type, stage, tumor tests and treatment plan decide whether nivolumab is used at all.
- Immune-related side effects can still happen. Immunotherapy can cause problems in the bowel, lungs, liver, skin and hormone glands, sometimes weeks or months after treatment starts.
- Real-world results are still being collected. NHS England notes that patient satisfaction data come from clinical trials.
What to do
If you are not taking nivolumab, there is nothing to do.
If you or someone you care for is on it, you can ask the care team:
- Is the under-the-skin version an option for me?
- Is it approved for my cancer type and my treatment combination?
- Does my insurance or health service cover it?
- Which side effects should make me call you, and how fast?
Do not ask to switch on your own, and do not stop treatment because of a headline.
To learn more, read our guides to nivolumab (Opdivo), immunotherapy, checkpoint inhibitors, immunotherapy side effects and when to call, and what clinical trials are.
Sources
- FDA, "FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection" (accessed 2026-10-05).
- NHS England, subcutaneous nivolumab rollout announcement, April 2025 (accessed 2026-10-05).
This page is general education. It is not medical advice and does not suggest a test or treatment.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to immunotherapy. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.